Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Is Merck Still a Strong Buy?

TheMotleyFool

0 0

Merck (NYSE: MRK) has long been the apple of investor's eyes, both for its excellent financials and solid dividend payouts. The company enjoyed monumental sales growth in Q3, with aggregate profits reaching $12.4 billion and an overall revenue surge of 15%.

Surpassing analyst's expectations, Merck elevated its full-year earnings outlook to the $46.5 billion to $47 billion range, which was a notable rise from the anticipated profits of $45.2 billion to $46.2 billion. While Merck is known for a variety of pharmaceutical products, there was one drug in particular that accounted for the better part of its profits and forecast boost in Q3: its blockbuster anti-cancer drug Keytruda.

Image Source: Getty Images

Source Fool.com

Like: 0

MRK

Teilen